STOCKS TELEGRAPH

Tag: SWAV stock

  • ShockWave Medical, Inc. (SWAV) stock gained in the after-hours; here is why?

    ShockWave Medical, Inc. (SWAV) gained in the after-hours market after announcing its fourth quarter and fiscal 2021 results. SWAV values at $147.49, losing more than 3% compared to yesterday’s closing price. The stock closed at $142.86 at the end of the last trading session. The stock volume traded in the last trading session was around 463.86K shares. The current market cap of the company is around $5.21 billion.

    SWAV: Key Financials

    • ShockWave Medical, Inc. (SWAV) revenue in Q4 2021 was $84.2 million. It is a gain of more than 271% compared to the revenue of Q4 in 2020.
    • Fiscal year revenue was $237 million, and it is an increase of more than 250% compared to the revenue in fiscal 2020.
    • The company’s net income in Q4 2021 was around $12.9 million. The net loss in Q4 2020 was around $15.9 million.
    • SWAV net income in fiscal 2021 was around $9.1 million. The company improved its loss from $65.7 million to $9.1 million in one year.
    • In Q4 2021, SWAV’s basic net income per share was $0.37. Diluted earnings per share were $0.34 in Q4 of 2021.
    • For fiscal 2021, the loss per share was $0.26.

    SWAV President and CEO’s Remarks

    Although faced with unexpected and unusual challenges, Shockwave Medical President and CEO Doug Godshall say his staff continues to perform effectively. In 2021, regulatory, sales, reimbursement, marketing, and operations performed well. He continued that employees and consumers have helped us improve patient outcomes for calcified vascular disease.

    SWAV 2022 Outlook

    During the entire year 2022, Shockwave Medical expects sales to be in the $405 million to $425 million range, an increase of 71-79 percent compared to revenues for the full year 2021.

    Conclusion

    The company’s stock has rallied in the after-hours due to its announcement of fiscal 2021 results. The debut of Shockwave C2 in February and the development of the US sales team and foreign distributor network drove revenue. Investors are investing in the stock due to its performance.

  • Shockwave Medical Inc. (SWAV) stock Soars After Hours. Here’s why?

    On January 07, Shockwave Medical Inc. (SWAV) stock gained a huge 16.55% in the after-hours session. According to reports on Bloomberg, Penumbra Inc. is exploring a business combination with the company. Hence, the stock seems to be gaining on the reports.

    SWAV closed the previous session at $169.02, suffering a loss of 4.89% at 581.35K shares. Following the unofficial reports, the stock soared after hours to reach $197.00 on Friday.

    The medical device company, Shockwave Medical Inc. was founded in 2009 and is based in Santa Clara, CA. Currently, the company has a market capitalization of $5.97 billion with its 35.3 million shares outstanding.

    SWAV Stock Movements

    Penumbra Inc. is a medical device company, based in Alameda, CA, with 13 office locations across five countries. Moreover, Penumbra has a market capitalization of $9.508 billion. Further, Penumbra is said to be exploring combination opportunities with Shockwave Medical, as per reports on Bloomberg. These reports caused the SWAV stock to soar high in the after-hours on Friday. Hence, the stock added a huge $27.98 in the after-hours session.

    To look at the bigger picture, SWAV stock has subtracted 5.22% in the past five days and 15.32% in the past three months. Furthermore, the stock has increased by 42.56% last year.

    Disrupt BTK II Post-Market Study

    On November 22, the company announced the commencing of Disrupt BTK II pots-market study. The study will evaluate the Shockwave Peripheral IVL System in the treatment of calcified peripheral lesions below the knee (BTK). Moreover, this will also include some of the most difficult critical limb ischemia (CLI) patients.

    Disrupt BTK II is led by Ehrin Armstrong, M.D. (Medical Director and Interventional Cardiologist, Adventist Heart and Vascular Institute) and Venita Chandra, M.D. (Vascular Surgeon and Clinical Associate Professor, Division of Vascular Surgery, Stanford Health Care). Furthermore, 250 patients would be enrolled in the study across 40 sites throughout the world.  In addition, the long-term durability of IVL will be tested and evaluated for two years in the patients.

    According to the announcement, the first patient in the Disrupt BTK II trial has been enrolled at the Midwest Cardiovascular Research Foundation by Dr. Nicolas Shammas.

    2022 Quarterly Earnings Release Dates

    On January 04, the company provided its quarterly earnings release dates for 2022. Accordingly, the earnings are expected to be reported as per the following details (after the market close):

    • Q4 2021: February 17, 2022
    • Q1 2022: May 9, 2022
    • Q2 2022: August 8, 2022
    • Q3 2022: November 7, 2022